DDInter1700 DDInter1435
Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Somatrem {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Somatrem {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Somatrem {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvastatin
Somatrem {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Somatrem {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Somatrem may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Somatrem may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Somatrem may lead to a major life threatening interaction when taken with Bexarotene